Lisanne de Koster

129 Diagnostic utility of molecular and imaging biomarkers 2 Table 12. Estimated pooled test performance of RAS mutation analysis in Bethesda IV thyroid nodules reference ni test + test - test ? nH (%) TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Moses 2010 110 8 102 0 110 (100%) 4 4 25 77 26% 14 (4-32) 95 (88-99) 2.79 (0.75-10.45) 0.91 (0.78-1.06) Nikiforov 2011 214 34 180 0 214 (100%) 29 5 29 151 27% 50 (37-63) 97 (93-99) 15.60 (6.34-38.37) 0.52 (0.40-0.67) Ohori 2013 424 50 334 40 384 (100%) 46 4 68 266 27% 40 (31-50) 99 (96-100) 27.24 (10.04-73.89) 0.61 (0.52-0.70) BeaudenonHuibregtse 2014 38 5 33 0 19 (50%) 4 1 2 12 16% 67 (22-96) 92 (64-100) 8.67 (1.21-61.91) 0.36 (0.12-1.13) Danilovic 2014 20 0 20 0 20 (100%) 0 0 7 13 35% 0 (0-41) 100 (75-100) 1.75 (0.04-80.00) 0.97 (0.79-1.19) Nikiforov 2014 143 24 119 0 143 (100%) 20 4 19 100 27% 51 (35-68) 96 (90-99) 13.33 (4.86-36.55) 0.51 (0.37-0.70) Giovanella 2015 61 4 57 0 61 (100%) 3 1 13 44 26% 19 (4-46) 98 (88-100) 8.44 (0.94-75.40) 0.83 (0.65-1.06) Rossi 2015 37 2 35 0 17 (46%) 1 1 7 8 22% 12 (0-53) 89 (52-100) 1.12 (0.08-15.19) 0.98 (0.69-1.40) Valderrabano 2016 58 13 44 1 37 (65%) 8 3 8 18 28% 50 (25-75) 86 (64-97) 3.50 (1.10-11.13) 0.58 (0.35-0.98) POOLED RESULTS 1,105 140 924 41 1,005 (94.5%) 115 23 178 689 26.5% 33.3 (21.1-48.3) 96.6 (94.3-98.0) 9.69 (4.94-19.0) 0.69 (0.56-0.85) FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.

RkJQdWJsaXNoZXIy MTk4NDMw